These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 8301879)

  • 21. PTPRC Expression in Blood is Downregulated in Parkinson's and Progressive Supranuclear Palsy Disorders.
    Bottero V; Santiago JA; Potashkin JA
    J Parkinsons Dis; 2018; 8(4):529-537. PubMed ID: 30248063
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A cerebrospinal fluid microRNA analysis: Progressive supranuclear palsy.
    Nonaka W; Takata T; Iwama H; Komatsubara S; Kobara H; Kamada M; Deguchi K; Touge T; Miyamoto O; Nakamura T; Itano T; Masaki T
    Mol Med Rep; 2022 Mar; 25(3):. PubMed ID: 35039873
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Increased levels of neuronal thread protein in cerebrospinal fluid of patients with Alzheimer's disease.
    de la Monte SM; Volicer L; Hauser SL; Wands JR
    Ann Neurol; 1992 Dec; 32(6):733-42. PubMed ID: 1471863
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Progressive supranuclear palsy affects both the substantia nigra pars compacta and reticulata.
    Hardman CD; Halliday GM; McRitchie DA; Cartwright HR; Morris JG
    Exp Neurol; 1997 Mar; 144(1):183-92. PubMed ID: 9126169
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Diagnostic value of blink reflex in multisystem atrophy, progressive supranuclear palsy and Parkinson disease.
    Szmidt-Salkowska E; Gawel M; Jamrozik Z; Salkowska-Wanat J; Gawel D; Kaminska A
    Neurol Neurochir Pol; 2016; 50(5):336-41. PubMed ID: 27591058
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CSF galanin and neuropeptide Y immunoreactivity in progressive supranuclear palsy.
    Litvan I; Berrettini WH; Atack JR; Chase TN
    Acta Neurol Scand; 1992 Aug; 86(2):204-6. PubMed ID: 1384261
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Application of the Unified Parkinson's Disease Rating Scale in progressive supranuclear palsy: factor analysis of the motor scale.
    Cubo E; Stebbins GT; Golbe LI; Nieves A; Leurgans S; Goetz CG; Kompoliti K
    Mov Disord; 2000 Mar; 15(2):276-9. PubMed ID: 10752576
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Levels of brain related proteins in cerebrospinal fluid: an aid in the differential diagnosis of parkinsonian disorders.
    Constantinescu R; Zetterberg H; Holmberg B; Rosengren L
    Parkinsonism Relat Disord; 2009 Mar; 15(3):205-12. PubMed ID: 18562238
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CSF biomarkers β-amyloid, tau proteins and a-synuclein in the differential diagnosis of Parkinson-plus syndromes.
    Constantinides VC; Paraskevas GP; Emmanouilidou E; Petropoulou O; Bougea A; Vekrellis K; Evdokimidis I; Stamboulis E; Kapaki E
    J Neurol Sci; 2017 Nov; 382():91-95. PubMed ID: 29111028
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cerebrospinal fluid levels of coenzyme Q10 are reduced in multiple system atrophy.
    Compta Y; Giraldo DM; Muñoz E; Antonelli F; Fernández M; Bravo P; Soto M; Cámara A; Torres F; Martí MJ;
    Parkinsonism Relat Disord; 2018 Jan; 46():16-23. PubMed ID: 29107645
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Diffuse Lewy body disease presenting with supranuclear gaze palsy, parkinsonism, and dementia: a case report.
    de Bruin VM; Lees AJ; Daniel SE
    Mov Disord; 1992 Oct; 7(4):355-8. PubMed ID: 1484531
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A network approach to diagnostic biomarkers in progressive supranuclear palsy.
    Santiago JA; Potashkin JA
    Mov Disord; 2014 Apr; 29(4):550-5. PubMed ID: 24347522
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Natural history of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) and clinical predictors of survival: a clinicopathological study.
    Litvan I; Mangone CA; McKee A; Verny M; Parsa A; Jellinger K; D'Olhaberriague L; Chaudhuri KR; Pearce RK
    J Neurol Neurosurg Psychiatry; 1996 Jun; 60(6):615-20. PubMed ID: 8648326
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Differential role of CSF fatty acid binding protein 3, α-synuclein, and Alzheimer's disease core biomarkers in Lewy body disorders and Alzheimer's dementia.
    Chiasserini D; Biscetti L; Eusebi P; Salvadori N; Frattini G; Simoni S; De Roeck N; Tambasco N; Stoops E; Vanderstichele H; Engelborghs S; Mollenhauer B; Calabresi P; Parnetti L
    Alzheimers Res Ther; 2017 Jul; 9(1):52. PubMed ID: 28750675
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Progressive supranuclear palsy presenting as primary lateral sclerosis but lacking parkinsonism, gaze palsy, aphasia, or dementia.
    Nagao S; Yokota O; Nanba R; Takata H; Haraguchi T; Ishizu H; Ikeda C; Takeda N; Oshima E; Sakane K; Terada S; Ihara Y; Uchitomi Y
    J Neurol Sci; 2012 Dec; 323(1-2):147-53. PubMed ID: 23026537
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Montreal Cognitive Assessment (MoCA) and Mini-Mental State Examination (MMSE) performance in progressive supranuclear palsy and multiple system atrophy.
    Fiorenzato E; Weis L; Falup-Pecurariu C; Diaconu S; Siri C; Reali E; Pezzoli G; Bisiacchi P; Antonini A; Biundo R
    J Neural Transm (Vienna); 2016 Dec; 123(12):1435-1442. PubMed ID: 27334897
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pattern of Tau forms in CSF is altered in progressive supranuclear palsy.
    Borroni B; Gardoni F; Parnetti L; Magno L; Malinverno M; Saggese E; Calabresi P; Spillantini MG; Padovani A; Di Luca M
    Neurobiol Aging; 2009 Jan; 30(1):34-40. PubMed ID: 17709155
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cerebrospinal fluid analysis for Whipple's disease in patients with progressive supranuclear palsy.
    Pezzella FR; Paglia MG; Colosimo C
    Mov Disord; 2004 Feb; 19(2):220-2. PubMed ID: 14978681
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A comparison of degeneration in motor thalamus and cortex between progressive supranuclear palsy and Parkinson's disease.
    Halliday GM; Macdonald V; Henderson JM
    Brain; 2005 Oct; 128(Pt 10):2272-80. PubMed ID: 16014651
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Different tau pathology pattern in two clinical phenotypes of progressive supranuclear palsy.
    Jellinger KA
    Neurodegener Dis; 2008; 5(6):339-46. PubMed ID: 18349518
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.